Matinas BioPharma to Participate in BTIG Virtual Biotechnology Conference
August 03 2021 - 7:30AM
Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced
that Jerome D. Jabbour, Chief Executive Officer, has been invited
to participate in a fireside chat as part of the BTIG Virtual
Biotechnology Conference on Tuesday, August 10, 2021 at 3:00 p.m.
ET. The Company will also host investor meetings during the
conference.
If you are interested in arranging a one-on-one
meeting or listening to the live event, please contact your BTIG
conference representative.
About Matinas BioPharma
Matinas BioPharma is a biopharmaceutical company
focused on improving the intracellular delivery of critical
therapeutics through its paradigm-changing lipid nanocrystal (LNC)
delivery platform. The Company is developing its own internal
portfolio of products as well as partnering with leading
pharmaceutical companies to develop new formulations that take full
advantage of the unique characteristics of the LNC platform.
Preclinical and clinical data have demonstrated that
this novel technology can provide solutions to many of the complex
challenges in achieving safe and effective intracellular delivery,
for both small molecules and larger, more complex molecules, such
as mRNA, DNA plasmids, antisense oligonucleotides and vaccines. The
combination of a unique mechanism of action and flexibility in both
the formulation and route of administration (including oral),
position Matinas’ LNC technology to potentially become the
preferred next-generation intracellular drug delivery vehicle and
an important improvement over both lipid nanoparticles and viral
vectors.
MAT2203 is an oral, LNC formulation of the
highly effective, but also highly toxic, antifungal medicine
amphotericin B, primarily used as a first-line treatment for
invasive fungal infections. MAT2203 is currently in a Phase 2
open-label, sequential cohort study (EnACT) in HIV-infected
patients with cryptococcal meningitis. EnACT is nearing the
completion of enrollment of its second cohort of patients, with the
next DSMB evaluation of safety and efficacy data anticipated to
occur in the third quarter of 2021.
MAT2501 is an oral, LNC formulation of the
broad-spectrum aminoglycoside antibiotic amikacin, primarily used
to treat chronic and acute bacterial infections. With the support
of the Cystic Fibrosis Foundation, MAT2501 is currently undergoing
important preclinical studies and expects to enter a Phase 1 human
clinical trial later in 2021. MAT2501 would be the first and only
oral aminoglycoside and is being positioned with an initial
indication for the treatment of nontuberculous mycobacterial (NTM)
lung disease, including infections in patients with cystic fibrosis
(CF).
LYPDISO™, is a prescription-only omega-3 fatty
acid-based composition, comprised primarily of EPA and DPA,
intended for the treatment of cardiovascular and metabolic
conditions. This next-generation omega-3 therapy has been shown in
two head-to-head studies to provide effective triglyceride-lowering
and significantly higher EPA blood levels than Vascepa®. The
Company has initiated a process to identity and secure a potential
partner to continue development of LYPDISO.
Forward-Looking Statements
This release contains "forward-looking
statements" within the meaning of the Private Securities Litigation
Reform Act of 1995, including those relating to the LNC platform
delivery technology, the Company’s strategic focus and the future
development of its product candidates, including MAT2203, MAT2501
and LYPDISO, the anticipated timing of regulatory submissions, the
anticipated timing of clinical studies, the anticipated timing of
regulatory interactions, the Company’s ability to identify and
pursue development and partnership opportunities for its products
or platform delivery technology on favorable terms, if at all, and
the ability to obtain required regulatory approval and other
statements that are predictive in nature, that depend upon or refer
to future events or conditions. All statements other than
statements of historical fact are statements that could be
forward-looking statements. Forward-looking statements include
words such as "expects," "anticipates," "intends," "plans,"
"could," "believes," "estimates" and similar expressions. These
statements involve known and unknown risks, uncertainties and other
factors which may cause actual results to be materially different
from any future results expressed or implied by the forward-looking
statements. Forward-looking statements are subject to a number of
risks and uncertainties, including, but not limited to, our ability
to obtain additional capital to meet our liquidity needs on
acceptable terms, or at all, including the additional capital which
will be necessary to complete the clinical trials of our product
candidates; our ability to successfully complete research and
further development and commercialization of our product
candidates; the uncertainties inherent in clinical testing; the
timing, cost and uncertainty of obtaining regulatory approvals; our
ability to protect the Company’s intellectual property; the loss of
any executive officers or key personnel or consultants;
competition; changes in the regulatory landscape or the imposition
of regulations that affect the Company’s products; and the other
factors listed under "Risk Factors" in our filings with the SEC,
including Forms 10-K, 10-Q and 8-K. Investors are cautioned not to
place undue reliance on such forward-looking statements, which
speak only as of the date of this release. Except as may be
required by law, the Company does not undertake any obligation to
release publicly any revisions to such forward-looking statements
to reflect events or circumstances after the date hereof or to
reflect the occurrence of unanticipated events. Matinas BioPharma’s
product candidates are all in a development stage and are not
available for sale or use.
Investor and Media Contacts
Peter
VozzoWestwicke/ICR443-213-0505peter.vozzo@westwicke.com
Matinas Biopharma (AMEX:MTNB)
Historical Stock Chart
From Aug 2024 to Sep 2024
Matinas Biopharma (AMEX:MTNB)
Historical Stock Chart
From Sep 2023 to Sep 2024